Evidence map›Paper›PMID 19086908›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2009

Adherence to hepatitis C virus therapy and early virologic outcomes.

Vincent Lo Re, Valerianna K Amorosa, A Russell Localio, Rose O'Flynn, Valerie Teal, Zachariah Dorey-Stein, Jay R Kostman, Robert Gross

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Review
  12. Article
  13. Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response.Liver international : official journal of the International Association for the Study of the Liver · 2013
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vincent Lo ReDivision of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, 423 Guardian Dr., Philadelphia, PA 19104-6021, USA. vincentl@mail.med.upenn.edu
Valerianna K Amorosa
A Russell Localio
Rose O'Flynn
Valerie Teal
Zachariah Dorey-Stein
Jay R Kostman
Robert Gross

Funding

CTRS FOR EDUCATION AND RESEARCH ON THERAPEUTICS (CERTS)U18HS010399 · AHRQ · UNIVERSITY OF PENNSYLVANIA · PI STROM, BRIAN LESLIE · 2000 to 2006
$800k
Risk factors and prediction of liver disease in HIV/HCVK01AI070001 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI LO RE, VINCENT · 2007 to 2011
$665k
AHRQ HHS HS 10399AHRQ HHS U18 HS010399NIAID NIH HHS K01 AI 070001NIAID NIH HHS K01 AI070001
6 · The paper itself

Abstract

backgroundSuboptimal drug exposure attributable to physician-directed dosage reductions of pegylated interferon and/or ribavirin are associated with decreased sustained virologic response rates. However, data are limited with regard to suboptimal drug exposure that is attributable to missed doses by patients with chronic hepatitis C virus (HCV) infection. We examined the relationship between adherence to pegylated interferon and ribavirin therapy, measured by pharmacy refill, and HCV suppression during the initial 12 weeks of therapy.

methodsWe conducted a cohort study involving 188 patients with chronic HCV infection who were treated with pegylated interferon plus ribavirin. Adherence was calculated using pharmacy refill data and could exceed 100%. The primary outcome was decrease in HCV load at 12 weeks; early virologic response was a secondary outcome. Mixed-effects regression models estimated the association between adherence and HCV suppression during the initial 12 weeks. Subanalyses were performed among patients who received optimal weight-based dosages.

resultsThe mean decrease in HCV load at 12 weeks was 0.66 log IU/mL greater for patients with > or =85% adherence than for those with <85% adherence (3.23 vs. 2.57 log IU/mL; P = .04). When patients who received a suboptimal ribavirin dosage were excluded, the decrease in viral load was 1.00 log IU/mL greater for persons with > or =85% adherence (3.32 vs. 2.32 log IU/mL; P = .01). Early virologic response was more common among patients with > or =85% adherence than it was among those with <85% adherence to treatment with pegylated interferon (73% vs. 29%; P = .02) and ribavirin (73% vs. 55%; P = .08).

conclusionsAdherence of > or =85% to pegylated interferon and ribavirin treatment was associated with increased HCV suppression. Decreases in HCV load became greater when patients with > or =85% adherence to their regimen continued to receive their recommended weight-based ribavirin dosage.

Indexed as

Medication AdherenceViral LoadAntiviral AgentsCohort StudiesFemaleHepatitis C, ChronicHumansInterferon-alphaInterferon alpha-2MaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsRegression AnalysisRibavirinTime FactorsAntiviral AgentsInterferon-alphaInterferon alpha-2peginterferon alfa-2bPolyethylene GlycolsRecombinant ProteinsRibavirin

Identifiers

PMID19086908
PMCPMC2668718

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.